Abstract | AIMS: METHODS: Serum levels of AGEs and CML-human serum protein (CML-HSP) were measured by a specific immunoassay in 51 men and 26 women aged 58 +/- 6.1 years (mean +/- SD) who had been treated for type II diabetes mellitus for 11 +/- 8 years, and in a non-diabetic control group consisting of 39 men and 21 women aged 55.5 +/- 7.5 years. Patients with macroalbuminuria or abnormal creatinine clearance were excluded from the study. RESULTS: The serum levels of AGEs were significantly increased in patients with type II diabetes compared to controls (P<0.001). Blood levels of CML-HSP were significantly increased in diabetic patients compared to normal subjects [35.3 +/- 27.4 and 9.3 +/- 7.2 (mean +/- SD) pmol/mg of protein, respectively; P<0.0001]. In diabetic patients with retinopathy or microalbuminuria (urinary albumin excretion: UAE > 30 mg/24 h), CML-HSP levels were significantly higher (P<0.02), and even more elevated in patients with both complications. CONCLUSION: In patients with type II diabetes, CML-HSP levels that are at variance with the HbA(1c) index for blood glucose may be a biomarker of glycoxidation, and related to the development of microvascular complications.
|
Authors | M P Wautier, P Massin, P J Guillausseau, M Huijberts, B Levy, E Boulanger, M Laloi-Michelin, J L Wautier |
Journal | Diabetes & metabolism
(Diabetes Metab)
Vol. 29
Issue 1
Pg. 44-52
(Feb 2003)
ISSN: 1262-3636 [Print] France |
PMID | 12629447
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Blood Glucose
- Glycation End Products, Advanced
- N(6)-carboxymethyllysine
- Lysine
|
Topics |
- Biomarkers
(blood)
- Blood Glucose
(metabolism)
- Body Mass Index
- Diabetes Mellitus, Type 2
(blood)
- Diabetic Angiopathies
(blood, diagnosis)
- Female
- Glycation End Products, Advanced
(blood)
- Humans
- Lysine
(analogs & derivatives, blood)
- Male
- Microcirculation
(physiology)
- Middle Aged
|